Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Pal, Sumanta K., Catherine Tangen, Ian M. Thompson, Naomi Balzer-Haas, Daniel J. George, Daniel Y. C. Heng, Brian Shuch, et al. “A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial.” Lancet 397, no. 10275 (February 20, 2021): 695–703. https://doi.org/10.1016/S0140-6736(21)00152-5.

PMID
33592176
Full Text

Zhang, Tian, Anika Agarwal, R Garland Almquist, Daniella Runyambo, Sally Park, Elizabeth Bronson, Rengasamy Boominathan, et al. “Expression of immune checkpoints on circulating tumor cells in men with metastatic prostate cancer.” Biomark Res 9, no. 1 (February 18, 2021): 14. https://doi.org/10.1186/s40364-021-00267-y.

PMID
33602330
Full Text

Patel, Anup, Alain Ravaud, Robert J. Motzer, Allan J. Pantuck, Michael Staehler, Bernard Escudier, Jean-François Martini, Mariajose Lechuga, Xun Lin, and Daniel J. George. “Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting.” Future Oncology (London, England) 17, no. 4 (February 2021): 403–9. https://doi.org/10.2217/fon-2020-0652.

PMID
33028084
Full Text

Shah, Anand, Thomas J. Polascik, Daniel J. George, John Anderson, Terry Hyslop, Alicia M. Ellis, Andrew J. Armstrong, et al. “Implementation and Impact of a Risk-Stratified Prostate Cancer Screening Algorithm as a Clinical Decision Support Tool in a Primary Care Network.” In J Gen Intern Med, 36:92–99, 2021. https://doi.org/10.1007/s11606-020-06124-2.

PMID
32875501
Full Text

Wilson, Lauren E., Lisa Spees, Jessica Pritchard, Melissa A. Greiner, Charles D. Scales, Christopher D. Baggett, Deborah Kaye, et al. “Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States.” Kidney Cancer 5, no. 3 (2021): 115–27. https://doi.org/10.3233/KCA-210119.

PMID
34632169
Full Text

Chen, Ronald C., Toni K. Choueiri, Marion Feuilly, Jie Meng, Johanna Lister, Florence Marteau, Aaron D. Falchook, Michael J. Morris, Daniel J. George, and Darren R. Feldman. “Quality-adjusted survival with first-line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance).” Cancer 126, no. 24 (December 15, 2020): 5311–18. https://doi.org/10.1002/cncr.33169.

PMID
33022096
Full Text

Shore, Neal, Celestia S. Higano, Daniel J. George, Cora N. Sternberg, Fred Saad, Bertrand Tombal, Kurt Miller, et al. “Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.” Prostate Cancer Prostatic Dis 23, no. 4 (December 2020): 680–88. https://doi.org/10.1038/s41391-020-0236-0.

PMID
32404868
Full Text

Brown, Landon C., Jason Zhu, Matthew K. Labriola, Yuan Wu, Sachica Cheris, Xin Liu, Kathryn Perkinson, et al. “PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.” Clin Genitourin Cancer 18, no. 6 (December 2020): 509–13. https://doi.org/10.1016/j.clgc.2020.03.020.

PMID
32482566
Full Text

Szymaniak, Brittany M., Lauren A. Facchini, Veda N. Giri, Emmanuel S. Antonarakis, Tomasz M. Beer, Maria I. Carlo, Daniel C. Danila, et al. “Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.” Jco Oncol Pract 16, no. 12 (December 2020): 811–19. https://doi.org/10.1200/OP.20.00431.

PMID
32986533
Full Text

Pages